BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma Review article
Article Sidebar
Published:
Jul 20, 2017
Keywords:
meloma, targeted therapy, BRAF inhibitora, MEK inhibitora
Main Article Content
Abstract
A major progress has been made in the systemic treatment of advanced melanoma over the last few years. Targeted therapy has proven highly active, which is reflected in the response rate as well as progression- free survival and overall survival times. The paper aims to summarize the current knowledge on the available BRAF and MEK inhibitors.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Kruczała M, Grela-Wojewoda A, Ziobro M. BRAF/MEK inhibitors in the systemic treatment of advanced skin melanoma. OncoReview [Internet]. 2017Jul.20 [cited 2024May5];7(3(27):139-43. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/466
Issue
Section
QUALITY OF LIFE IN ONCOLOGY
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Online: http://onkologia.org.pl/czerniak-skory-c43/.
2. Wojciechowska U, Ditkowska J. Poprawa przeżyć chorych na nowotwory złośliwe w Polsce Analiza przeżyć pacjentów zdiagnozowanych w latach 2003-2005. Nowotwory J Oncol 2013; 63: 279-285.
3. Świtaj T, Falkowski S, Rutkowski P et al. Systemowe leczenie rozsianego czerniaka. In: Rutkowski P (ed.): Złośliwe nowotwory skóry. Via Medica, Gdańsk 2014: 135-137.
4. Świtaj T, Nowecki Z, Rutkowski P. Leczenie ukierunkowane czerniaków skóry. In: Wojtukiewicz M, Sierko E (ed.): Leczenie ukierunkowane na cele molekularne w onkologii i hematoonkologii. Via Medica, Gdańsk 2013: 420-438.
5. Woodman SE, Lazar AL, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clin Cancer Res 2012; 18: 1195-1200.
6. Long GV, Menzies AM, Nagrial AM et al. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. J Clin Oncol 2011; 29:1239-1246.
7. Summary of Product Characteristics Zelboraf®.
8. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
9. Online: http://www.roche-trialscom/studyResultGetaction?studyResultNumber=MO25653.
10. Summary of Product Characteristics Tafinlar®.
11. Ascierto PA, Minor D, Ribas A et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31(26): 3205-3211. https://doi.org/101200/JCO2013498691.
12. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
13. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAKMB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13(11): 1087-1095. https://doi.org/101016/S1470-2045(12)70431-X.
14. Long G, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888.
15. Long G, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-451.
16. Schadendorf D, Hodi F, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33(17): 1889-1894. https://doi.org/101200/JCO2014562736.
17. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39.
18. Larkin J, Ascierto P, Dreno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876.
19. Larkin J, Yan Y, Mcarthur G et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 2015; 33: 9006.
20. Ascierto P, McArthur G, Dreno B et al. Cobimetinib combined with vemurafenib in advanced BRAFV600 mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17(9): 1248-1260.
21. Schreurer M, Jansen Y, Planken S et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol 2017; 18(4): 464-472. DOI: 101016/S1470- 2045(17)30171-7.
22. Valpione S, Catlino M, Mangana J et al. Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. J Clin Oncol 2017; 35(suppl; abstr 9512): 9512-9512.
2. Wojciechowska U, Ditkowska J. Poprawa przeżyć chorych na nowotwory złośliwe w Polsce Analiza przeżyć pacjentów zdiagnozowanych w latach 2003-2005. Nowotwory J Oncol 2013; 63: 279-285.
3. Świtaj T, Falkowski S, Rutkowski P et al. Systemowe leczenie rozsianego czerniaka. In: Rutkowski P (ed.): Złośliwe nowotwory skóry. Via Medica, Gdańsk 2014: 135-137.
4. Świtaj T, Nowecki Z, Rutkowski P. Leczenie ukierunkowane czerniaków skóry. In: Wojtukiewicz M, Sierko E (ed.): Leczenie ukierunkowane na cele molekularne w onkologii i hematoonkologii. Via Medica, Gdańsk 2013: 420-438.
5. Woodman SE, Lazar AL, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. Clin Cancer Res 2012; 18: 1195-1200.
6. Long GV, Menzies AM, Nagrial AM et al. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. J Clin Oncol 2011; 29:1239-1246.
7. Summary of Product Characteristics Zelboraf®.
8. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
9. Online: http://www.roche-trialscom/studyResultGetaction?studyResultNumber=MO25653.
10. Summary of Product Characteristics Tafinlar®.
11. Ascierto PA, Minor D, Ribas A et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31(26): 3205-3211. https://doi.org/101200/JCO2013498691.
12. Hauschild A, Grob JJ, Demidov LV et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
13. Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAKMB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13(11): 1087-1095. https://doi.org/101016/S1470-2045(12)70431-X.
14. Long G, Stroyakovskiy D, Gogas H et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371: 1877-1888.
15. Long G, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-451.
16. Schadendorf D, Hodi F, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33(17): 1889-1894. https://doi.org/101200/JCO2014562736.
17. Robert C, Karaszewska B, Schachter J et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-39.
18. Larkin J, Ascierto P, Dreno B et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-1876.
19. Larkin J, Yan Y, Mcarthur G et al. Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM: phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated melanoma. J Clin Oncol 2015; 33: 9006.
20. Ascierto P, McArthur G, Dreno B et al. Cobimetinib combined with vemurafenib in advanced BRAFV600 mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17(9): 1248-1260.
21. Schreurer M, Jansen Y, Planken S et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol 2017; 18(4): 464-472. DOI: 101016/S1470- 2045(17)30171-7.
22. Valpione S, Catlino M, Mangana J et al. Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. J Clin Oncol 2017; 35(suppl; abstr 9512): 9512-9512.